Addex Therapeutics Ltd - ADR

The momentum for this stock is not very good. Addex Therapeutics Ltd - ADR is not a good value stock. Addex Therapeutics Ltd - ADR is not very popular among insiders. Addex Therapeutics Ltd - ADR is a mediocre stock to choose.
Log in to see more information.

News

Are Medical Stocks Lagging  Addex Therapeutics (ADXN) This Year?
Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year?

Zacks Investment Research Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Addex Therapeutics Ltd. Sponsored ADR (ADXN) been one of those stocks this...\n more…

Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Globe Newswire Geneva, Switzerland, September 4, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric...\n more…

HC Wainwright Comments on Addex Therapeutics Ltd's FY2024 Earnings (NASDAQ:ADXN)
HC Wainwright Comments on Addex Therapeutics Ltd's FY2024 Earnings (NASDAQ:ADXN)

Ticker Report Addex Therapeutics Ltd (NASDAQ:ADXN - Free Report) - Equities researchers at HC Wainwright dropped their FY2024 earnings estimates for shares of Addex Therapeutics in a note issued to investors on...\n more…

HC Wainwright Comments on Addex Therapeutics Ltd's Q1 2025 Earnings (NASDAQ:ADXN)
HC Wainwright Comments on Addex Therapeutics Ltd's Q1 2025 Earnings (NASDAQ:ADXN)

Ticker Report Addex Therapeutics Ltd (NASDAQ:ADXN - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Addex Therapeutics in a research report...\n more…

Addex Therapeutics (NASDAQ:ADXN) Given Buy Rating at HC Wainwright
Addex Therapeutics (NASDAQ:ADXN) Given Buy Rating at HC Wainwright

Ticker Report HC Wainwright reaffirmed their buy rating on shares of Addex Therapeutics (NASDAQ:ADXN - Free Report) in a report released on Wednesday morning, Benzinga reports. They currently have a $30.00 price...\n more…

Crude Oil Dips; Addex Therapeutics Shares Spike Higher
Crude Oil Dips; Addex Therapeutics Shares Spike Higher

Benzinga U.S. stocks traded mostly lower midway through trading, with the Dow Jones index falling around 0.2% on Tuesday. The Dow traded down 0.16% to 41,175.13 while the NASDAQ fell 0.03% to 17,720.68. The S&P 500 also fell, dropping, 0.01% to 5,616.66.\n more…